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ROMAOvarianmasses, a common finding among pre- and post-menopausal women, can be benign ormalignant. Ovar-
ian cancer is the leading cause of death from gynecologic malignancy among women living in industrialized
countries. According to the current guidelines, measurement of CA125 tumor marker remains the gold standard
in themanagement of ovarian cancer. Recently, HE4 has been proposed as emerging biomarker in the differential
diagnosis of adnexal masses and in the early diagnosis of ovarian cancer. Discrimination of benign andmalignant
ovarian tumors is very important for correct patient referral to institutions specialized in care andmanagement of
ovarian cancer. Tumor markers CA125 and HE4 are currently incorporated into the “Risk of Ovarian Malignancy
Algorithm” (ROMA)withmenopausal status for discerningmalignant frombenign pelvicmasses. The availability
of a good biomarker such as HE4, closely associated with the differential and early diagnosis of ovarian cancer,
could reduce medical costs related to more expensive diagnostic procedures. Finally, it is important to note
that HE4 identifies platinum non-responders thus enabling a switch to second line chemotherapy and improved
survival.
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Ovarian masses represent a common finding among both pre- and
post-menopausal women. The reported prevalence varies widely de-
pending upon the population studied, the criteria employed and the
imaging equipment. Ovarian masses can be benign or malignant and
include neoplasms, ovarian endometriomas and lesions of functional
or inflammatory origin. Epithelial ovarian cancer is the most frequent
malignant tumor accounting for 70% of malignant neoplasms [1]. The
number of women diagnosed with a benign adnexal mass is much
higher than the number of ovarian cancer cases. In pre-menopause,
most ovarianmasses are benign. The overall incidence of ovarian cancer
in pre-menopause is approximately 1:1000 increasing to 3:1000 at the
age of 50 [2]. Ovarian masses are also common in post-menopausal
women, although the prevalence is lower than in pre-menopausal
women. Ovarian carcinoma (OC) is the leading cause of death from gy-
necologic cancer for women living in industrialized countries [3]. At the
present, the global annual incidence is approximately 204,499 cases per
year with a mortality of 124,860 patients per year [4]. The expected
number of new ovarian cancer cases in Europe in 2012 was 65,538
with 42,704 deaths [1]. If carcinoma is diagnosed at an early stage, it
has an excellent prognosis since it can be treated before spreading to
surrounding tissue [5].
Currently, as many as 70% of patients are diagnosed at International
Federation of Gynecology and Obstetrics (FIGO) stage III and IV. This
late diagnosis is generally related to the asymptomatic behavior of the
disease in the early stages. Although certain epithelial ovarian cancer
screening tests have been shown to decrease mortality rates, the possibi-
lity of efficient screening that may be used in normal practice remains
elusive [6].
It is crucial to correctly characterize whether ovarian masses are
benign or malignant.
Patients with diagnosed ovarian cancer should be treated in specia-
list units that provide themost comprehensive cancer care [7], whereas
in cases of benign ovarian masses expectant or conservative surgical
management should be performed in order to reduce morbidity and
fertility preservation [8]. In fact, in premenopausal women preservation
of fertility is an important issue. Although these women are rarely
thought to have cancer, they in fact account for up to 20% of all ovarian
malignancies [9]. Even in selected cases of early stage invasive disease or
borderline ovarian tumors (BOT), conservative treatment is a therapeu-
tic option in youngwomenwhowant to preserve childbearing capacity
[8,10,11].
Prediction models have been developed to assist clinicians to triage
patients to appropriate treatment pathways; however, none has gained
universal acceptance in routine daily practice. Most of these algorithms
include the serum CA125 biomarker and this limits their utility in
women of reproductive age [12]. Serum CA125 levels are frequently
normal in BOT and early stage invasive ovarian cancer [13], and can
show a false positive increase in numerous benign tumors or conditions
that irritate the pelvic peritoneum (e.g. endometriosis, fibroids, preg-
nancy, infection and surgery) [14].
Recently, human epididymis protein 4 (HE4) has been proposed as
emerging biomarker in the differential diagnosis of pelvic masses.
Currently a combination of physical examination and serum bio-
marker measurement are the pillar of medical diagnosis. Serum
CA125, newly discovered HE4 and imaging have the highest positive
predictive value (PPV): 33.8% in pre- and 74.0% in post-menopausal
women [15].The lack of early symptoms to guide timely image-driven investiga-
tions, severely limits the possibility of detecting the disease at its early
stages. Availability of sensitive and specific ovarian cancer biomarkers
is very much needed to reduce the mortality risk due to late diagnosis.
The objective of this review is to assess the overall diagnostic value
of measuring HE4 for the differential diagnosis of ovarian masses and
Epithelial Ovarian Cancer identification.
2. Genetic biomarkers
Tumors are caused by the accumulation of genetic injuries, but the
genetic mutations and pathways involved in the early ovarian carcino-
genesis are largely unknown. Since the close relationship between ge-
netic alterations and ovarian carcinogenesis, during the last decade,
the study of researchers has been focused on providing novel ovarian
cancer biomarkers [5].
Gene mutations in BRCA1 and BRCA2 account for the majority of
families with hereditary breast and ovarian cancer syndrome [16]. The
risk of developing ovarian cancer in a woman with a BRCA1 mutation
is 39–46%, while it is 12–27% in a woman with a BRCA2 mutation [17].
Despite substantial improvement in managing ovarian cancer risks
owing to BRCA1/BRCA2 mutations, the guidelines recommend prophy-
lactic bilateral salpingo-oophorectomy (PO) by age 40 years. Guiding
recommendations about these interventions are difficult, as the relative
risk for either BRCA1 or BRCA2 mutations have been proposed being
different [18].
Previous studies showed that both BRCAproteins participate inmul-
tiple functions, such as DNA repair, transcriptional regulation of gene
expression, and cell cycle [19].
Actually, advances in genomic technologies quicken the finding of
other cancer susceptibility genes. To date, at least 16 genes, including,
RAD51C, RAD51D, BRIP1, BARD1, CHEK2, MPE11A, NBN, PALB2, RAD50,
MLH1, MSH2, MSH6, PMS2, and TP53 have been associated with hered-
itary ovarian cancer [6].
The gene-expression profiling can be a considerable biomarker for
early detection of ovarian cancer, allowing various information includ-
ing prognosis, prediction of chemotherapy response, mechanisms of
chemoresistance, and finally the characterization of different histologic
or genetic subtypes. The rapid advances in new generation sequencing
(NGS) technology in terms of higher throughput and lower cost,
together with the development of multiple genomic sequence enrich-
ment methods, have contributed significantly to both the research and
clinical applications of cancer genome sequencing.
It is now widely expected that the second generation sequencing
will offer the in-depth characterization of the cancer cell genome and
further advance the fields of pathogenesis of cancer and personalized
oncology for patients.
3. Epithelial ovarian cancer
Epithelial Ovarian Cancer (EOC) is the most common type, which is
further divided into endometrioid, clear cell, mucinous, low-grade
serous ovarian carcinoma (LGSOC), and high-grade serous ovarian car-
cinoma (HGSOC). HGSOC is the most common and aggressive subtype
of EOC, accounting for the majority of new cases [20]. HGSOC was
long thought to arise from the ovarian surface epithelium (OSE) or
inclusion cysts derived from them, but recent evidence has recognized
the distal fimbrial epithelium of the fallopian tube as the font for at
least a subset of HGSOC.
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EOC, much effort has been dedicated to the genetic modification of
cells from an OSE or fimbrial origin, either in tissue culture or in vivo.
Attempts to model HGSOC have been particularly challenging and
have yielded inconsistent results [21]. On the basis of a series of mor-
phologic andmolecular genetic studies, it has been proposed a dualistic
model that groups various types of epithelial ovarian cancers into two
broad categories, nominated type I and type II.
Type I tumors include low-grade serous, low-grade endometrioid,
mucinous, and clear cell carcinomas. These neoplasms typically present
as large cystic masses restricted to one ovary; have a relatively indolent
course; and are associated with mutations in KRAS, BRAF, PTEN, PIK3CA,
CTNNB1, ARID1A, and PPP2R1A that disturb signaling pathways. These
molecular alterations result in morphologic changes, which are
reflected by a stepwise progression from benign through varying
degrees of atypia (borderline tumor), then to noninvasive and finally
to invasive and metastatic carcinoma.
Type II tumors are collected of high-grade serous, high-grade
endometrioid, undifferentiated carcinomas, and malignant mixed me-
sodermal tumors (carcinosarcomas). These tumors are aggressive and
typically present at an advanced stage, which adds to their high morta-
lity rate. Unlike type I tumors, which are relatively genetically stable,
type II tumors demonstrate several chromosomal aberrations at diagno-
sis, but these remain relatively stable over the course of the disease [21].
4. Ovarian serum biomarkers
The role of tumor markers in diagnosing and monitoring ovarian
cancer is well established [22]. The current benchmark biomarker for
ovarian cancer detection CA125 was originally identified following the
development of the OC 125 antibody for the coelomic epithelial antigen
produced themesothelial cells from the peritoneal, pleural, and pericar-
dial cavities. It has been used to predict the presence of malignancy in
women with a pelvic mass, monitor response to chemotherapy, and
detect relapse after initial response to treatment [23,24].
The mucin CA125 has a high sensitivity, but its clinical use in the
management of EOC patients is limited because it is also frequently
elevated in women with other malignancies and with benign gyne-
cologic disorders as well as benign diseases associated with inflamma-
tory conditions of the pleura, pericardium, and peritoneum [25,26].
However, according to the current guidelines measurement of serum
CA125 antigen remains the gold standard in the follow-up EOC [26].
In the recent years, research has focused on new biomarkers such as
mesothelin, inhibin, osteopontin and Ca72.4 even if the benefits of these
markers are unclear, as, although sensitivity is increased, specificity is
sub-optimal [27–30].
4.1. Mesothelin
The mesothelin gene encodes a 71-kDa precursor protein that
undergoes physiological cleavage by a furin like protease to produce
twomain proteins, the first is the 31-kDa NH2-terminal megakaryocyte
potentiation factor (MPF), which is secreted into the blood, the second
COOH-terminal product is a 40-kDa fragment referred to asmesothelin,
which is attached to the cell membrane and is overexpressed in several
cancers, including mesothelioma, ovarian and pancreatic cancers, and
some squamous cell carcinomas. In patients with ovarian carcinoma,
Scholler et al. [31] have described a 42 to 44-kDa protein termed soluble
mesothelin-related peptide (SMRP). These findings indicate that a high
expression of mesothelin in both tissue and serum indicates a poor
prognosis. Themechanismof release ofmesothelin from the cell surface
is not clear. Many studies showed that serummesothelin levels are re-
lated to the FIGO surgical pathological staging and pathological grade
in EOC patients. Patients with advanced stage and low differentiation
tumors showed higher levels of SMRP most recent study reported the
expression of mesothelin in ovarian tissue correlated to chemotherapyresistance and poor prognosis suggesting a role for mesothelin in diag-
nosis and disease staging [32].
4.2. Inhibin
Inhibins were initially isolated from gonadal fluids based on their
relevant abilities to inhibit follicle stimulating hormone (FSH) secretion
from the pituitary. Successively, these proteins were recognized as
members of a family of growth factors, the transforming growth
factor-beta (TGFb) superfamily, with multiple functions as confined
regulators of gonadal biology. Inhibin A and Inhibin B act as antagonists
and are structural homologues of activins, including the activin b-
subunit and a unique a-subunit.
It has been validated that the alteration of the inhibin/activin
pathway may contribute to the development of epithelial ovarian
cancer due to the alteration of the crosstalk between granulosa and
epithelial cells [33].
In a recent study, Walentowicz et al. propose the association of high
levels of inhibin A with a poor prognosis and a low survival at 5 years
[33].
4.3. Osteopontin
Osteopontin (OPN) is a secreted, integrin-binding phosphoprotein
that has been associated with cancer and is overexpressed in different
tumor types [34]. Physiologically, OPN is secreted by osteoblasts and
the epithelial cells of multiple organs as well as by activated T lympho-
cytes, macrophages and leukocytes at the site of inflammation. Some
authors showed that OPN-c, an OPN splicing variant, contributed to
the increased proliferation, migration and invasion of ovarian cancer
cells [35,36]. However, this glycoprotein is strongly associated with
progressive tumor stage, poor patient prognosis and metastasis
formation. Although several studies have focused on the role of OPN
in ovarian cancer screening, the utility of OPN for differentiating
betweenmalignant and benign ovarian tumors has not been sufficiently
elucidated.
4.4. Carbohydrate antigen 72-4
Carbohydrate antigen 72-4 (CA72.4) is another biomarker for EOC;
the level of this 200–400 kDa glycoprotein rises in gastric, cholic, breast,
and ovarian adenocarcinomas. It can be used alone or in association
with CA125. The sensitivity of CA72.4 is lower than CA125 in detecting
EOC, but the levels of this marker are not affected by pregnancy or the
menstrual period. There is evidence in the literature that CA72.4 levels
can be found slightly increased with endometriosis, benign ovarian
tumors, or inflammatory conditions [37,38].
Some authors have demonstrated the role of the biomarker CA72.4
combined with CA125 as a predictive factor of epithelial ovarian cancer
recurrence( ).
Moore RG et al. 2007 showed that the combination of more tumor
markers including HE4, together with CA72.4 increased the sensitivity
and specificity in the diagnosis of ovarian cancer in patients with pelvic
masses [39].
5. Human epididymis protein 4 (HE4): a new biomarker
5.1. Gene and protein biology
Recently, human epididymis protein 4 (HE4) has been proposed as
emerging biomarker in EOC differential diagnosis, it allows a differential
diagnosis from pelvic mass, can detect the disease at early stage, and for
monitoring the response to chemotherapy and to estimate the progno-
sis of ovarian cancer.
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mis. This protein was discovered to be a protease inhibitor involved in
sperm maturation [40,41].
This protein has a WAP-type four-disulfide core (WFDC) domain
and is encoded by the WFDC2 gene. It is suggested that those genes
evolved by repeated duplications. Genes at theWFDC locus are variably
conserved across species and may play a role in natural immunity with
both antimicrobial and anti-inflammatory activity. The HE4 gene
extends over 8 kb DNA and contains five exons. Full-length HE4 is the
result of splicing of exons 1, 2, 4, and 5. Exons 3 and 4 can exist in
three forms, two of which can be spliced. Intracellular immunofluores-
cence studies revealed that HE4 is distributed in a region of the cyto-
plasm with a perinuclear pattern reminiscent of the endoplasmic
reticulum and the Golgi [42].
Its role as a potential biomarker for ovarian cancer emerged after
cDNA comparative hybridization experiments based on the observation
of an increased primary expression of HE4 in some ovarian cancers,
relative to normal tissues [43].
5.2. Analytical methods
5.2.1. Enzyme-linked immunosorbent assay (EIA)
HE4 can be measured by immunometric techniques: manual
or semi-automated enzyme-linked immunosorbent assay (EIA),
chemiluminescent microparticle immunoassay (CMIA) and electro-
chemiluminescence immunoassay (ECLIA) automated.
The first evaluation method to detect HE4 was solid phase EIA, non-
competitive immunoassay based upon the direct “sandwich” technique
using two monoclonal antibodies, 2H5 and 3D8, directed against two
epitopes in the C-WFDC domain of HE4. This assay has been developed
for the determination of HE4 in human serum. The HE4 based enzyme-
linked immunosorbent assay recognizes full-length HE4 and splice
variants V2 and V3, but not splice variants V1 and V4. This assay is
characterized by an equivalent sensitivity, but a higher specificity com-
pared to theCA125 betweenmalignant and benign adnexalmasses [44].
5.2.2. Chemiluminescent microparticle immunoassay (CMIA)
The ARCHITECT HE4 assay (Abbott Diagnostics Division, Chicago,
USA) is a two-step chemiluminescent microparticle immunoassay
(CMIA) for the quantitative determination of HE4 antigen in human
serum. Differences between the commercial EIA method (Fujirebio
Diagnostics) and the ARCHITECT HE4 assay (Abbott Diagnostics
Division) are the technology for signal detection (colorimetric vs. chemi-
luminescent), the measurement ranges (15–900 pmol/L for EIA and
20–1500 pmol/L for CMIA with an automated 1:10 dilution protocol
that extends the linear range up to 15,000 pmol/L).
5.2.3. Electrochemiluminescence immunoassay (ECLIA)
TheCobas Electrochemiluminescence utilizes a specificity chemilumi-
nescence reaction on the electrode surface induced by the electrochemi-
cal reaction. It is actually the perfect combination of electrochemical
reaction and chemiluminescence reaction. The measuring ranges for
HE4 with ECLIA is 15.0–1500 pmol/L.
With the method EIA and ECLIA the suggested cut-off is 150 and
140 pmol/L respectively, while using the CMIA procedure the cut-offTable 1
Laboratory test used to detection of HE4.
Manufacturer
kit
Standard range
pmol/L
Limit
pmol/
Manual EIA Fujrebio® 15–900 15
Automated CMIA Abbott® 20–1500 0.18
Automated ECLIA Roche® 15–1500 15proposed is 70 pmol/L in premenopausal women and 140 pmol/L in
postmenopausal women (Table 1).
However, it is important to consider that for HE4, as for many tumor
markers, is not correct to express the result as positive or negative, since
has not been validated a diagnostic cut-off.
Clinically important variations in HE4 serum concentration occur on
the basis of age among healthy women, which underscores the need
to address specific age subgroups. Further studies will be required
determining whether trends of HE4 values provides even greater
specificity, as is the case with CA 125.
5.3. Clinical relevance
Various factors aside from malignancy may influence serum HE4
levels and should be carefully considered in interpreting the results of
HE4 [45,46].
HE4 levels in healthy subjects increased with age and smoking
habitus, but its serum levels are not affected by the menstrual cycle,
oral contraceptive use or endometriosis [47–51] (Table 2). Conversely,
elevated HE4 levels have been observed in patients with chronic renal
disease which may result from decreased elimination or increased
production from the damaged renal tubules [52]. However it should
clarify the relationship between HE4 levels and early stage renal failure.
The elevated HE4 serum concentrations detected in patients with renal
failure resolutely suggested that HE4 must be interpreted carefully in
patients with renal failure. This is important, because acute renal failure
may be frequently present in some patients during chemotherapy
treatment.
The most important uses of HE4 in EOC are: differential diagnosis,
“Risk of Ovarian Malignancy Algorithm" (ROMA), and screening. The
prognostic value of this biomarker is still controversial. Indeed, Jiang
et al. [53] suggest that HE4 overexpression enhanced several malignant
phenotypes in cell culture and in a mouse model, while Kong X et al.
[54] conversely, found that HE4 plays a protective role in the progres-
sion of EOC by inhibiting cell proliferation, this effect is mediated by in-
tracellular HE4, which may function by regulating the MAPK and PI3K/
Akt signal transduction pathway in vitro.
6. Differential diagnosis of ovarian masses
In the past, when ultrasoundwas not routinely used, the presence of
a palpable ovarian mass in a postmenopausal woman was considered
an indication to surgery with bilateral salpingo-oophorectomy [55].
More recent studies suggest the possibility to perform a conservative
management in these patients according to the ultrasonographic
characteristics of the cyst, the CA125 value and the patient's preference.
Identification of the subgroup of patients most likely to benefit from
consultation with a gynecologic oncologist may be a clinical challenge.
Differential diagnosis can be sometime difficult but it is mandatory
particularly in the presence of benign conditions such as small ovarian
endometrioma, that do not necessarily require surgical treatment [29].
Discriminating benign frommalignant disease is important not only
to ensure appropriate management by a gynecologic oncology surgeon
in the setting of malignancy, but also to avoid unnecessary procedures,
including surgery, and anxiety in women with asymptomatic, nonma-
lignant conditions. To date, no single prediction model or set of referralof detection
L
Precision
% CV
Cut-off
pmol/L
≤15 b150
≤10 b70 premenopausal
b140 postmenopausal
≤10 b140
Table 2
Comparison of CA125 vs. HE4 in benign gynecologic diseases.
Benign disease CA125
Menopausal
status
HE4
Menopausal status
Pre Post Pre Post
Ovarian cyst 15% 13% 6% 13%
Germ cell tumors 19% 25% 2% 0%
Cystadenomas 20% 22% 20% 19%
Benign, non-specified 35% 18% 5% 14%
Endometriosis/endometrioma 72% 18% 3% 6%
Abscess/PID/hydrosalpinx 40% 33% 13% 13%
Menstruation Elevated – Not elevated –
First trimester pregnancy Elevated – Not elevated –
Infertility Elevated – Not elevated –
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spread acceptance.
A careful and documented assessment of the patient should be
performed according to the current guidelines. Clinical assessment
always includes family history, physical examination, imaging, and
laboratory tests (including CA125 results, if available). A physical
examination of the woman is essential and should include abdominal
and vaginal examination. In the presence of acute pain the diagnosis
of ovarian cyst torsion, rupture or hemorrhage should be considered.
According to the Dearking modified ACOG guidelines, suspicion
criteria of an ovarian cancer are:
in premenopause:
a) Very elevated CA125 (N67 units/mL);
b) Ascites;
c) Evidence of abdominal or distant metastasis;
in postmenopause:
a) Elevated CA125 (N35 units/mL);
b) Nodular or fixed pelvic mass;
c) Ascites;
d) Evidence of abdominal or distant metastasis.
As already reported, CA125 is unreliable in differentiating benign
from malignant ovarian masses in premenopausal women because of
the increased rate of false positives. In these women CA125 levels can
behigh in benign gynecological diseases such as endometriosis,fibroids,
pelvic infections, but also in physiological conditions such as pregnancy
or different phases of the menstrual cycle [56,57]. HE4 level is not
influenced by pregnancy or the menstrual cycle phase and it never
increases in patients with endometriosis or other benign ovarian
masses [58,59]. Therefore HE4 may be the best biomarker in premeno-
pausal women. Imaging is used to detect and characterize adnexal
masses and to stage ovarian cancer both before and after initial treat-
ment, although the role for imaging in screening for ovarian cancer
has not been established.
The risk of encountering an unexpected ovarian malignancy after
modern preoperative screening is 0.9% to 13% [60].
Transvaginal ultrasonography (TVUS) is the first line of imaging to
study an adnexal mass. TVUS evaluates the size, structure (cystic, solid
or mixed), the vascularization with the use of power-color doppler
and the relationship with the surrounding structures. Over the past
several years scoring system have been proposed to provide more
objective criteria in discrimination between benign and malignant
masses with a sensitivity close to 100% and specificity vary between
84 and 92%.
In order to use a common descriptive language for ultrasound read-
ings, and better compare the data a study IOTA (International OvarianTumor analysis, still ongoing), has compiled an accurate classification
of ovarian masses based on the content of the mass, the surface, the
walls, the septa, the presence of papillary vegetations and the vascular-
ization. This classification distinguishes different types of adnexal le-
sions: unilocular, unilocular solid multilocular, multilocular solid, solid.
Some masses cannot be classified due to poor visualization (large cone
shadow due to calcification as in some dermoid cysts) [61]. The study
IOTA 2010 proposes an index of risk of malignancy based on the sono-
graphic findings, the state of menopause and the serum concentration
of CA125 suggesting a score ultrasound (U) from 0 to 3 according to
multilocularity, the solid component, the bilateral presences of masses
and the presence of ascites and eventual metastasis [61]. According to
the literature about 8% of the lesions remain indeterminate at adnexal
sonographic investigation. In this group are included lesions such as
the tumors with low degree of malignancy, mucinous forms, fibroids
and struma ovarii. In these cases the use of biomarkers together with
imaging could be an important tool to formulate the diagnosis. Indeed,
the high value of HE4 in a complexmass is strongly indicative formalig-
nant lesion [62]. These tumors have proven difficult to classify with
transvaginal ultrasound, and remain a diagnostic challenge for which
accurate second-stage tests would be performed.
Several authors report magnetic resonance imaging (MRI) as the
best method to investigate pelvic female thanks to the multiparametric
capabilities of the method. MRI is used in the evaluation of benign con-
ditions such as endometriosis and in the staging of malignant lesions of
the uterus [63,64].
A correct diagnosis of any adnexal mass is essential to define appro-
priate treatment pathways. Some studies suggest that MRI, compared
with other imagingmodalities, may play a role in the assessment of ad-
nexal masses ‘difficult to classify’ Conventional MRI combined with dy-
namic contrast-enhanced and Diffusion Weighted Imaging (DWI) may
play a critical role in this cohort of patients [65].
Multi-detector computed tomography ( MDCT) is the procedure of
choice for preoperative staging of ovarian cancer and to determine the
resectability of tumors. Recent studies show thatMDCThad a sensitivity
of approximately 93%with a specificity ranging between 91 and 96% for
lesions larger than one centimeter. These parameters dramatically fail
for lesions less than 0.5 cm in diameter, with a sensitivity that, in
these cases, is around43% [66]. Sensitivity reaches 100%, for implants lo-
cated at the level of the hepatic dome, in the evaluation of the degree of
infiltration of the liver parenchyma [67].
PET–CT (positron emission tomography–computed tomography) is
a reliable imaging technique for suspected recurrence, particularly in
women with rising CA125 levels, in the presence of negative results of
conventional imaging.
In the follow-up is very important to correlate the level of bio-
markers with imaging.
It is interesting to note that HE4 combined with sophisticated
imaging techniques is a goodmarker for the early diagnosis. In addition,
HE4 serum levels combined with MDCT may improve the monitoring
management of women affected by ovarian cancer [68]. However,
PET-CT demonstrates high sensitivity (75–97%) and accuracy ranging
(92–96%). Those parameters are higher than those reported for MDCT
(SE 61–92%) [69].
The PET–CT demonstrates a higher level of accuracy in the detection
of para-aortic lymph node involvement and peritoneal metastases, this
is even greater than the accuracy for recurrence at the vaginal dome
[70].
7. Risk of malignancy algorithm: ROMA
Subsequently the discovery of serum HE4, researches have focused
on its role in differentiating between epithelial ovarian cancer and
benign masses. HE4 was combined in two high-risk disease evaluate
formulas, called “risk of malignancy algorithm” (ROMA) formulated
for premenopausal and for postmenopausal women with adnexal
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agnostic power of the CA125 and HE4 markers with menopausal status
lacking the imaging evaluation. This algorithm has been approved by
the FDA as a useful indicator for differentiating malignant from benign
pelvic masses. Although this index has been enhanced as a diagnostic
instrument, high ROMA scores have been also reported to be indepen-
dently associatedwith a negative prognosis in some patients with ovar-
ian cancer [71].
Many studies report that ROMA algorithm implement better in the
premenopausal population than in the postmenopausal women. A pre-
dicted probability (PP) greater than 13.1% suggests a high risk in the
premenopausal women, whereas PP value higher than 27.7% indicates
a high risk in the postmenopausal women. Using this algorithm, 93.8%
of epithelial ovarian cancers were correctly defined as high risk [70,
72]. ROMA sensitivity and specificity suggests its use for the triage of
woman with an adnexal mass to gynecologic oncologist [73–82]
(Table 3). Currently the role of ROMA is controversial, to elucidate the
clinical relevance of this algorithm numerous international studies
were designed.
Unfortunately, the studies are not consistent with each other, prob-
ably due to the different numbers of patients investigated, the different
geographical origins, and finally the different analytical systems used.
Actually this quick approach does not solve all the problems related to
the differential diagnosis of pelvic masses. Potential limitations or ben-
efits of ROMA in clinical management will be better investigated.8. Screening
Despite recent advances in ovarian cancer cure, new methods of
early detection remain of paramount importance, because they have
the potential to clearly improve long-term survival. However, a number
of novel insights into disease etiology, evolution and biomarker discov-
ery suggest that a new era in screening is underway [83].
Longitudinal studies are ongoing in several countries to evaluate
screening strategies using CA125 and/or transvaginal sonography and
their impact on overall cancer detection and mortality. Other current
serummarkers that have been identified up to now have not proven ad-
equate sensitivity or specificity for screening. Thus, new biomarkers that
could improve the early detection for ovarian cancer are critically needed.
In the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial,
investigators evaluated some 35 different biomarkers in proximal
prediagnostically collected serum samples from 118 women who subse-
quently developed ovarian cancer. In evaluating samples that were ob-
tained before conventional diagnosis, the addition of 7 biomarkers to
CA125 in a combined multimarker panel did not improve sensitivity
over that obtained with CA125 alone at 98% specificity [57–84].
Despite this observation, it is encouraging that Anderson et al. [85]
demonstrated a progressive increase in CA125 and HE4 between 1
and 3 years before diagnosis of ovarian cancer.
Currently, a phase I screening trial is underway to evaluate the vali-
dity of HE4 in a first/second-line multimodal screening strategy thatTable 3
CA125 and HE4 performance in ROMA.
Author Study size CA125 analytical method
Moore RG [73] 472 CMIA
Karlsen MA [74] 1218 CMIA
Van Gorp T [75] 432 EIA
Jacob F [76] 160 EIA
Lenhard M [77] 535 CMIA
Molina R [78] 527 CMIA
Montagnana M [79] 153 EIA
Ruggeri G [80] 259 CMIA
Ortiz-Munoz B [81] 279 ECLIA
Anton C [82] 120 ECLIAcombines CA125, HE4 and transvaginal at high risk for ovarian cancer
[86].
9. Medical strategies
Standard initial treatment of epithelial ovarian cancer includes
surgery to optimally cyto-reduce cancerwithin the peritoneal cavity be-
fore the initiation of cytotoxic chemotherapy. Although no randomized
controlled trials have demonstrated the superiority of thismanagement
approach comparedwith beginning chemotherapy after histologic con-
firmation of the presence of a malignancy consistent with the diagnosis
of ovarian cancer, extensive retrospective data have demonstrated that
patients with the smallest volume of residual cancer within the perito-
neal cavity before initiation of chemotherapy achieve the longest sur-
vival. Although the definitive value of surgery is unknown, in most
patients it can be safely performed by qualified gynecologic oncologic
surgeons. Under these circumstances, there seems to be little justifica-
tion to deny a patient the potential, although not proven, benefits of
surgery.
Considerable uncertainty within the gynecologic cancer community
remains regarding the importance of achieving a particular degree of
cyto-reduction. Traditionally, based on considerable retrospective
data, a patient has been classified as having “optimal residual disease”
if the maximum diameter of the largest residual tumor nodule present
within the peritoneal cavity at the completion of surgery is b1 cm
[87]. However, some surgical groupshave challenged this concept by ar-
guing that patients who have all microscopic cancer within the perito-
neal cavity removed have a substantially superior survival compared
with patients in whom any macroscopic cancer remains. In the opinion
of these surgical groups, the goal of surgery should be to achieve this
state even if it requires extensive radical surgery, including in the
upper abdomen, liver, and chest. Further examination of the clinical rel-
evance of the extent of surgery in achieving an optimal residual disease
level is indicated [88].
Large numbers of phase III trials have been conducted during the
past 30 years that have sequentially helped to define the current stan-
dard of care in the chemotherapeutic management of advanced ovarian
cancer [89].
Carboplatin/paclitaxel has been widely accepted as the standard of
care in treating primary EOC. Many studies have demonstrated similar
progression-free survival (PFS) and overall survival (OS) between the
standard of care and the various alternates regimens [90,91].
Approaches that have been examined and found to be no better than
the current gold standard include: 1) doubling the dose intensity of the
platinum drug, 2) high-dose systemic chemotherapy[92], 3) extending
the duration of the paclitaxel infusion (from 24 to 96 h), and 4) adding
one of several biologically active third drugs to the platinum/taxane
doublet [91].
However, findings from a report from Japanese investigators have
revealed that the delivery of paclitaxel on a weekly schedule improves
both progression-free and overall survival compared with the standard
every-3-week paclitaxel regimen in patients with advanced ovarianHE4 analytical method Specificity Sensibility NPV
EIA 75% 93% 90%
CMIA 76% 94% –
EIA 77% 85% 83%
EIA 86% 79% –
CMIA 95% 77% –
CMIA 88% 90% 96%
EIA 81% 74% –
EIA 75% 96% –
ECLIA 91% 93% 98%
EIA 76% 74% –
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are provided by 2 phase III studies in breast cancer that have revealed
the superiority of weekly paclitaxel (compared with the every-3-week
schedule) [94]. Preclinical data have suggested that paclitaxel may
have clinically relevant antiangiogenic effects, and it is possible that
the weekly drug delivery schedule may optimize this biological effect.
Weekly cisplatin, however, was not found to impart any benefit when
compared with its standard regimen.
Three multicenter National Cancer Institute cooperative group trials
have reported superior progression-free and overall survival rates asso-
ciated with intraperitoneal administration of cisplatin compared with
intravenous delivery of the agent in the primary treatment of small-
volume residual advanced ovarian cancer, a finding confirmed in a
meta-analysis of randomized trial data [95]. Although the definition of
“small volume” differed among the studies, the most recent trials de-
fined eligible patients as those whose largest residual cancerous mass
was b1 cm in maximum diameter after surgical cyto-reduction.
According to the current guidelines measurement of serum CA125
antigen remains the gold standard in the follow-up EOC. HE4 has pro-
posed as emerged and promising biomarkers capable of following the
remission from disease as monitoring response to therapy. The sugges-
tion that HE4 is a good indicator for the remission from the disease was
recently reported by follow-up studies, in which it was shown that the
values of HE4 correlated with the clinical response to treatment or re-
mission from the disease, as documented by CT imaging [96]. Interest-
ingly, in patients with recurrence of the increased expression of HE4
preceded by up to 5–8months the CA125. In addition, other studies sug-
gest that the evaluation of serum HE4 changes could improve the as-
sessment of response to chemotherapy in patients affected by EOC.
Interestingly, it has been demonstrated that high HE4 levels at third
chemotherapy cycle are significantly associated with the platinum-
based chemotherapy response, therefore HE4 is able to identify theplat-
inum non responding patients with the possibility to switch to second
line chemotherapy and with the opportunity to improve the surviv-
al[97]. Thismeans thatHE4 is not only a good indicator for the remission
from illness but, being able to anticipate its expression, compared to
that of CA125, is an ideal EOC marker for therapeutic strategies against
relapse [98].
10. Conclusions
Ovarian cancer is an issue of great importance to public health. Early
diagnosis is very important for a better chance of survival. Up to now the
only clinically serummarker accepted for the diagnosis and follow-up of
ovarian carcinomas is the CA125, which presents, as known, diagnostic
limitations. Recently, themeasurement of HE4 has proposed for the dif-
ferential diagnosis of ovarian cancer in women with pelvic mass. This
review supports the diagnostic role of serum HE4 alone or in combina-
tion with CA125. It may be a valuable approach for distinguishing pa-
tients with ovarian endometrioma or other benign adnexal masses
from those with ovarian malignancy. Differentiating between benign
and malignant diseases is very important for correct referral of patients
to institutions specialized in the care and management of EOC. More-
over, HE4 compared to CA125, is potentially a better marker for the
early diagnosis and could be an important initial indicator of the recur-
rence of the disease and promising prognostic factor of EOC. In addition,
preoperative levels of HE4 were intensely linked to EOC prognostic fac-
tors because significantly enhance with age, FIGO stage, grade and re-
sidual tumor. Additionally, HE4 serum levels, reflected the course of
the disease during and after chemotherapy. It is relevant that the con-
gruence of HE4 outline with the disease progression, also suggest that
the determination of the changes in serum concentrations of HE4 can
help to evaluate the response to treatment and early relapse in patients
with EOC and that HE4 is a good indicator for the remission from the
disease with the clinical response to treatment as documented by CT
imaging.Finally, for a correct evaluation of theHE4performance, it is essential
to consider the influence of age, menstrual status, smoking habits and
renal function. As occurs for many other tumor markers, a decrease in
renal function leads to a significant increase of HE4. This is not an irrel-
evant question even considering that patients in follow-up may have
renal failure due to chemotherapy. The availability of a good tumor
marker for the differential diagnosis, early detection, treatment and re-
currence of EOC, could reduce medical costs related to more expensive
diagnostic procedures and itmay have a reassuring effect on the patient.
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